Pomyelo 4mg Capsule (Pomalidomide)

The Pomyelo 4mg Capsule contains pomalidomide, an oral immunomodulatory anticancer medicine used mainly for multiple myeloma. It binds to cereblon and alters the activity of proteins involved in myeloma-cell survival and immune regulation. Pomalidomide 4mg Capsule is generally used in combination with dexamethasone and, in some settings, other anticancer medicines for patients who have received previous treatment. It can cause severe birth defects and significant blood-count suppression, so strict pregnancy-prevention measures and regular monitoring are essential. Pomyelo 4mg Capsule is a prescription medicine and must be used only under specialist supervision. Patients should not donate blood or share the medicine with anyone.

For current Pomyelo 4mg capsule availability, in the present day, a licensed pharmacy or authorized oncology medication supplier in India could be consulted. Availability of the medication must be established before ordering, and its use must be on the recommendation of the oncologist alone.

Pomalidomide 4mg Capsule is used for selected adults with relapsed or refractory multiple myeloma after prior therapy, according to the approved label and treatment setting. It is commonly combined with low-dose dexamethasone and may be incorporated into multi-drug regimens with other myeloma therapies. Eligibility depends on previous treatments, disease response, blood counts, kidney and liver function, clotting risk, and other patient factors. Because pomalidomide capsules are related to thalidomide and are highly teratogenic, treatment must follow strict pregnancy-prevention requirements.

Pomyelo is an immunomodulatory agent that binds cereblon, a component of an E3 ubiquitin ligase complex. This alters degradation of transcription factors such as Ikaros and Aiolos and changes tumor-cell survival and immune signaling. In multiple myeloma, these effects can suppress malignant plasma cells and enhance immune-mediated activity. Pomalidomide 4mg Capsule is also strongly teratogenic and can cause significant myelosuppression and thromboembolic complications, so strict risk-management measures are required.

Evidence context: The studies below are pivotal or widely cited evidence supporting the Pomyelo 40mg Capsule in major treatment settings. Trial results should not be interpreted as a guarantee of benefit for an individual patient, and exact eligibility must match the current approved indication and oncology guideline.

Pomyelo 4mg Capsule may cause side effects, and their frequency varies by indication, dose, combination regimen, and patient population. The list below highlights clinically important effects rather than assigning a single percentage across different trials.

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Fatigue
• Constipation or diarrhea
• Infections
• Back or bone pain
• Shortness of breath

Serious side effects

• Embryo-fetal toxicity
• Venous / arterial thromboembolism
• Febrile neutropenia / serious infection
• Severe liver or skin reactions

For multiple myeloma, a standard labelled regimen is 4 mg orally once daily on days 1-21 of each 28-day cycle, usually with dexamethasone and sometimes additional agents depending on the treatment plan. Swallow capsules whole, with or without food. Dose interruption and reduction are required for neutropenia, thrombocytopenia, and other significant toxicity. Renal/hepatic impairment and strong CYP1A2 inhibition can alter dosing or exposure.

Administration guidance: Take the Pomyelo 4mg Capsule exactly according to the cycle prescribed by the hematologist, commonly once daily on specified treatment days of a 28-day cycle. Swallow the capsule whole with water; do not open, break, or chew it. It can generally be taken with or without food and should be taken at about the same time each day. Blood counts are monitored regularly, and the dose may be interrupted or reduced for neutropenia, thrombocytopenia, or other toxicity. Strict pregnancy-prevention requirements must be followed. Do not share capsules and do not donate blood during treatment with the Pomalidomide 4mg Capsule and for the required period afterwards.​

Follow the product-specific missed-dose rule. Do not take two doses together. If a substantial delay has occurred, the missed dose is generally skipped; contact the treatment team if uncertain.

Strict pregnancy-prevention requirements and pregnancy testing are mandatory under applicable risk-management programs. Monitor CBC frequently, especially during early cycles, and monitor liver function. Assess thrombosis risk and use prophylaxis when indicated by the treating hematologist. Evaluate fever urgently.

Practical monitoring checklist

• Complete blood count (CBC) at the label/protocol-recommended intervals
  

• FDA Pomalyst (pomalidomide capsule) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204026s019lbl.pdf
• EMA Imnovid Product Information / SmPC. https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445​
• National library of medicine. Pomalidomide 4mg: A novel drug to treat multiple myeloma. https://pmc.ncbi.nlm.nih.gov/articles/PMC3656921/​
• Nature. Leukemia. https://www.nature.com/articles/leu2017156​